أعرض في EDS

Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358

التفاصيل البيبلوغرافية
العنوان: Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358
المؤلفون: A. Horvath, Tai-Tsang Chen, Kathleen N. Moore, José María López-Picazo, Y.-J. Bang, Ana Oaknin, Valentina Boni, J.C. Park, R.W. Naumann, Lot A. Devriese, Christopher D. Lao, William H. Sharfman, K. Zaki, Tim Meyer, K. Harano, Christine H. Chung, Bin Li, Junchen Gu, Suzanne L. Topalian, Adam Barrows
المصدر: Annals of Oncology. 30:v898-v899
بيانات النشر: Elsevier BV, 2019.
سنة النشر: 2019
مصطلحات موضوعية: Oncology, Cervical cancer, medicine.medical_specialty, business.industry, Cancer, Ipilimumab, Hematology, Pembrolizumab, medicine.disease, Interim analysis, Response Evaluation Criteria in Solid Tumors, Internal medicine, medicine, Progression-free survival, Nivolumab, business, medicine.drug
تدمد: 0923-7534
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::bcb2f5660c4ccf28d277727e2f0db35eTest
https://doi.org/10.1093/annonc/mdz394.059Test
حقوق: OPEN
رقم الانضمام: edsair.doi...........bcb2f5660c4ccf28d277727e2f0db35e
قاعدة البيانات: OpenAIRE
الوصف
تدمد:09237534